Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Dec 5;25(1):6.
doi: 10.1208/s12248-022-00773-3.

End-to-End Approach to Surfactant Selection, Risk Mitigation, and Control Strategies for Protein-Based Therapeutics

Annette Medina Morales  1 , Alavattam Sreedhara  2 , Jakob Buecheler  3 , Sebastian Brosig  3 , Danny Chou  4 , Twinkle Christian  5 , Tapan Das  6 , Isabella de Jong  2 , Jonas Fast  7 , Bharat Jagannathan  5 , Ehab M Moussa  8 , M Reza Nejadnik  9 , Indira Prajapati  10 , Allison Radwick  11 , Yusra Rahman  9 , Shubhadra Singh  12
Affiliations

End-to-End Approach to Surfactant Selection, Risk Mitigation, and Control Strategies for Protein-Based Therapeutics

Annette Medina Morales et al. AAPS J. .

Erratum in

Abstract

A survey performed by the AAPS Drug Product Handling community revealed a general, mostly consensus, approach to the strategy for the selection of surfactant type and level for biopharmaceutical products. Discussing and building on the survey results, this article describes the common approach for surfactant selection and control strategy for protein-based therapeutics and focuses on key studies, common issues, mitigations, and rationale. Where relevant, each section is prefaced by survey responses from the 22 anonymized respondents. The article format consists of an overview of surfactant stabilization, followed by a strategy for the selection of surfactant level, and then discussions regarding risk identification, mitigation, and control strategy. Since surfactants that are commonly used in biologic formulations are known to undergo various forms of degradation, an effective control strategy for the chosen surfactant focuses on understanding and controlling the design space of the surfactant material attributes to ensure that the desired material quality is used consistently in DS/DP manufacturing. The material attributes of a surfactant added in the final DP formulation can influence DP performance (e.g., protein stability). Mitigation strategies are described that encompass risks from host cell proteins (HCP), DS/DP manufacturing processes, long-term storage, as well as during in-use conditions.

Keywords: Control strategy; Formulation stability; In use compatibility; Poloxamer; Polysorbate; Surfactant.

PubMed Disclaimer

References

    1. Number of products and pipeline count per modality for commonly used surfactants. 22 December 2021.
    1. Bam NB, Randolph TW, Cleland JL. Stability of protein formulations: investigation of surfactant effects by a novel EPR spectroscopic technique. Pharm Res. 1995;12(1):2–11. - PubMed
    1. Misono T, et al. Surface adsorption and micelle formation of polyoxyethylene-type nonionic surfactants in mixtures of water and hydrophilic imidazolium-type ionic liquid. J Oleo Sci. 2016;65(6):499–506. - PubMed
    1. Khan T, Mahler H-C, Kishore R. Key interactions of surfactants in therapeutic protein formulations: a review. Eur J Pharm Biopharm. 2015;97.
    1. Bam NB, et al. Tween protects recombinant human growth hormone against agitation-induced damage via hydrophobic interactions. J Pharm Sci. 1998;87(12):1554–9. - PubMed

LinkOut - more resources